Overview
- 4 inspections across 4 sites are on record.
- 4 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2023-12-06.
At a glance
Inspections
4
Sites
4
Observations
4
Career since
Aug 2019
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Carsgen Therapeutics Corporation | 6 Dec 2023 | Biologics | On file |
| Celgene Corporation | 19 Feb 2021 | Biologics | On file |
| Juno Therapeutics, Inc. | 16 Oct 2020 | Biologics | On file |
| Novartis Pharmaceuticals Corporation | 21 Aug 2019 | Biologics | View 483 → |
Sites inspected
Carsgen Therapeutics CorporationDurham, United States1 insp.
Celgene CorporationSummit, United States1 insp.
Juno Therapeutics, Inc.Bothell, United States1 insp.
Novartis Pharmaceuticals CorporationMorris Plains, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Nirjal Bhattarai2 shared
Latorie S Jones1 shared
Travis S Bradley1 shared
Nimmy Mathews1 shared
Linda Thai1 shared
David E Bailey1 shared
Rabia Ballica1 shared
Prabhu P Raju1 shared
Eileen A Liu1 shared
Jacqueline M Diaz Albert1 shared
Full investigator report
Get the verbatim findings behind Kimberly L Schultz's 4 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site